SKU:K1299 | M. Wt:436.26 | ||
Formula:C19H9Cl2F2N3OS | Solubility:No | ||
Purity:>99% | Storage:2 years -20°C Powder | ||
CAS No.:209410-46-8 | Synonyms:N/A | ||
Chemical NameN/A |
供货周期: | 一周 |
品牌: | |
规格: | 2mg |
货号: | K1299 |
CAS号: | 209410-46-8 |
SKU:K1299 | M. Wt:436.26 | ||
Formula:C19H9Cl2F2N3OS | Solubility:No | ||
Purity:>99% | Storage:2 years -20°C Powder | ||
CAS No.:209410-46-8 | Synonyms:N/A | ||
Chemical NameN/A |
Description | VX-745 | |||||
---|---|---|---|---|---|---|
Targets | p38-alpha MAPK | p38-beta MAPK | ||||
IC50 | 10 nM | 220 nM | ||||
In vitro | VX-745,a lead anti-inflammatory candidate, is a small-molecule inhibitor of mitogen-activated protein kinase (MAPK). VX-745 inhibits interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) secretion in bone marrow stromal cells (BMSCs), without affecting their viability. VX-745 can also inhibit tumor necrosis factor alpha (TNF-alpha)-induced IL-6 secretion in BMSCs. VX-745 inhibits both MM cell proliferation and IL-6 secretion in BMSCs triggered by adherence of MM cells to BMSCs. VX-745 can inhibit paracrine MM cell growth in the BM milieu and overcome cell adhesion-related drug resistance. VX-745 potently inhibited TNF release from LPS stimulated human THP-1 cells with IC50s of 29 nM. | |||||
In vivo | VX-745 is effective against adjuvant-induced arthritis (AA) in the rat with ED50 of 5 mg/kg. Histological scores for VX-745 in AA rats are 93% inhibition of bone resorption and 56% inhibition of inflammation. | |||||
Clinical Trials | N/A | |||||
Features | N/A |
相关产品
重组人肌球蛋白轻链2(Recombinant Human MYL2)
重组大鼠抵抗素(Rat Resistin)
大鼠酸性磷酸酶(ACP)ELISA Kit
大鼠胆囊收缩素/缩胆囊素八肽(CCK-8)ELISA Kit
人瘦素(LEP)ELISA Kit
重组人半乳糖凝集素16/LGALS16 Human
重组人半乳糖凝集素8/Human LGALS8 His
重组人半乳糖凝集素3/Human LGALS3 His
重组人卵泡抑素/Human FST His
重组人β防御素118/DEFB118 Human
重组人心肌营养素1/CTF1 Human
特级新生牛血清(无支原体)
超级新生牛血清(无支原体)
优级胎牛血清(无支原体)
特级新生牛血清(无噬菌体低内毒素)
详细地址
关注
拨打电话
留言咨询